Objetivo: Avaliar marcadores de reserva ovariana e a presença de anticorpo anti-corpo lúteo (anti-CoL) em pacientes com arterite de Takayasu (AT) e possível associação com parâmetros clínicos, laboratoriais e uso de imunossupressores. Métodos: 20 pacientes com AT e 24 controles saudáveis foram avaliados para anti-CoL (immunoblot). A reserva ovariana foi avaliada por: hormônio folículo estimulante (FSH), hormônio luteinizante (LH), estradiol, hormônio anti-Mülleriano (HAM) e contagem de folículos antrais (CFA). HAM foi dosado por ELISA utilizando dois diferentes testes. Dados demográficos, obstétricos, alterações menstruais, aspectos clínicos, imagens vasculares e tratamento foram também analisados. Resultados: A média da idade atual foi similar em pacientes e controles (31,2 ± 6,1 vs. 30,4 ± 6,9 anos, p = 0,69). As frequências de HAM baixo foram idênticas em pacientes com AT com ambos os testes de ELISA e maiores quando comparadas ao grupo controle (50% vs.17%, p=0,02, 50% vs. 19%, p=0,048). Observou-se uma correlação positiva entre os dois testes de ELISA em pacientes (r=0,93, p < 0,0001) e em controles saudáveis (r=0,93, p < 0,0001). Pacientes com AT apresentaram menor CFA (11 vs. 16, p=0,13) e maior frequência de CFA reduzida (41% vs. 22%, p=0,29), contudo sem significância estatística. Não foram encontradas diferenças entre os dois grupos em relação às outras características demográficas e clínicas, dados obstétricos e demais parâmetros da reserva ovariana (p > 0,05). Anti-CoL foi observado apenas em uma paciente com AT (5% vs. 0%, p = 0,45). Avaliação adicional das mulheres com AT comparando as com baixos níveis de HAM ( < 1,0 ng/mL) versus aquelas com níveis de HAM QRUPD ng/mL) não mostrou diferença entre os dois grupos em relação a duração da doença, atividade de doença, provas de fase aguda, exames de imagem vascular e tratamento (p > 0,05). Conclusão: O presente estudo foi o primeiro a sugerir que as pacientes com AT podem apresentar reserva ovariana diminuída / Objective: To assess ovarian reserve markers and anti-corpus luteum antibodies (anti-CoL) in Takayasu arteritis (TA) patients and a possible association with clinical and laboratory parameters and the use of immunosuppressive drugs. Methods: 20 TA and 24 healthy controls were evaluated for anti-CoL (immunoblot). Ovarian reserve was assessed by: follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, antiMüllerian hormone (AMH) and antral follicle count (AFC). AMH was measured by ELISA using two different kits. Demographical data, menstrual abnormalities, obstetric data, clinical features, vascular imaging and treatment were also analyzed. Results: The mean current age was similar in TA patients and controls (31.2 6.1 vs. 30.4 6.9 years, p=0.69). The frequencies of decreased levels of AMH in TA patients were identical using both kits and higher when compared to controls (50% vs. 17%, p=0.02; 50% vs. 19%, p=0.048). A positive correlation was observed between the two kits in TA patients (r=+0.93; p < 0.0001) and in healthy controls (r=+0.93; p < 0.0001). The apparent lower AFC (11 vs. 16, p=0.13) and the higher frequency of low AFC (41% vs. 22%, p=0.29) in TA compared to controls did not reach statistical significance. No differences between the two groups were found concerning other demographic and clinical characteristics, obstetric data and other parameters of ovarian reserve (p > 0.05). Anti-CoL was solely observed in TA patients (5% vs. 0%, p=0.45). Further evaluation of TA patients comparing patients with low AMH levels ( < 1.0ng/mL) versus normal AMH levels (.- 1.0ng/mL) revelead no differences regarding disease duration, disease activity, acute phase reactants, vascular imaging and treatment between these two groups (p > 0.05). Conclusions: The present study was the first to suggest that TA patients may have diminished ovarian reserve

Objetivo: Avaliar marcadores de reserva ovariana e a presença de anticorpo anti-corpo lúteo (anti-CoL) em pacientes com arterite de Takayasu (AT) e possível associação com parâmetros clínicos, laboratoriais e uso de imunossupressores. Métodos: 20 pacientes com AT e 24 controles saudáveis foram avaliados para anti-CoL (immunoblot). A reserva ovariana foi avaliada por: hormônio folículo estimulante (FSH), hormônio luteinizante (LH), estradiol, hormônio anti-Mülleriano (HAM) e contagem de folículos antrais (CFA). HAM foi dosado por ELISA utilizando dois diferentes testes. Dados demográficos, obstétricos, alterações menstruais, aspectos clínicos, imagens vasculares e tratamento foram também analisados. Resultados: A média da idade atual foi similar em pacientes e controles (31,2 ± 6,1 vs. 30,4 ± 6,9 anos, p = 0,69). As frequências de HAM baixo foram idênticas em pacientes com AT com ambos os testes de ELISA e maiores quando comparadas ao grupo controle (50% vs.17%, p=0,02, 50% vs. 19%, p=0,048). Observou-se uma correlação positiva entre os dois testes de ELISA em pacientes (r=0,93, p < 0,0001) e em controles saudáveis (r=0,93, p < 0,0001). Pacientes com AT apresentaram menor CFA (11 vs. 16, p=0,13) e maior frequência de CFA reduzida (41% vs. 22%, p=0,29), contudo sem significância estatística. Não foram encontradas diferenças entre os dois grupos em relação às outras características demográficas e clínicas, dados obstétricos e demais parâmetros da reserva ovariana (p > 0,05). Anti-CoL foi observado apenas em uma paciente com AT (5% vs. 0%, p = 0,45). Avaliação adicional das mulheres com AT comparando as com baixos níveis de HAM ( < 1,0 ng/mL) versus aquelas com níveis de HAM QRUPD ng/mL) não mostrou diferença entre os dois grupos em relação a duração da doença, atividade de doença, provas de fase aguda, exames de imagem vascular e tratamento (p > 0,05). Conclusão: O presente estudo foi o primeiro a sugerir que as pacientes com AT podem apresentar reserva ovariana diminuída / Objective: To assess ovarian reserve markers and anti-corpus luteum antibodies (anti-CoL) in Takayasu arteritis (TA) patients and a possible association with clinical and laboratory parameters and the use of immunosuppressive drugs. Methods: 20 TA and 24 healthy controls were evaluated for anti-CoL (immunoblot). Ovarian reserve was assessed by: follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, antiMüllerian hormone (AMH) and antral follicle count (AFC). AMH was measured by ELISA using two different kits. Demographical data, menstrual abnormalities, obstetric data, clinical features, vascular imaging and treatment were also analyzed. Results: The mean current age was similar in TA patients and controls (31.2 6.1 vs. 30.4 6.9 years, p=0.69). The frequencies of decreased levels of AMH in TA patients were identical using both kits and higher when compared to controls (50% vs. 17%, p=0.02; 50% vs. 19%, p=0.048). A positive correlation was observed between the two kits in TA patients (r=+0.93; p < 0.0001) and in healthy controls (r=+0.93; p < 0.0001). The apparent lower AFC (11 vs. 16, p=0.13) and the higher frequency of low AFC (41% vs. 22%, p=0.29) in TA compared to controls did not reach statistical significance. No differences between the two groups were found concerning other demographic and clinical characteristics, obstetric data and other parameters of ovarian reserve (p > 0.05). Anti-CoL was solely observed in TA patients (5% vs. 0%, p=0.45). Further evaluation of TA patients comparing patients with low AMH levels ( < 1.0ng/mL) versus normal AMH levels (.- 1.0ng/mL) revelead no differences regarding disease duration, disease activity, acute phase reactants, vascular imaging and treatment between these two groups (p > 0.05). Conclusions: The present study was the first to suggest that TA patients may have diminished ovarian reserve

A Arterite de Takayasu (AT) é uma vasculite granulomatosa de aorta e grandes vasos associada a elevado risco cardiovascular. A velocidade de onda de pulso (VOP) é um método de avaliação indireta de diminuição da distensibilidade arterial, e valores elevados de VOP correlacionam-se com maior morbimortalidade cardiovascular. A avaliação da VOP em pacientes com arterite de Takayasu é complexa devido a muitos fatores de confusão. O objetivo do presente estudo foi avaliar a rigidez arterial, por meio da velocidade de onda de pulso carótido-femoral (VOP-CF) em pacientes do sexo feminino com arterite de Takayasu e controles saudáveis com variáveis clínicas e antropométricas comparáveis, e sua possível associação com os parâmetros da doença. Método: Pacientes com arterite de Takayasu (n = 27) foram avaliados consecutivamente e foram selecionados controles saudáveis com idade, pressão arterial, peso e altura comparáveis (n = 27). Os critérios de exclusão foram menopausa, tabagismo, diabetes, insuficiência renal, hipertensão mal controlada, arritmias cardíacas, obesidade, comorbidades inflamatórias, gravidez e história de procedimentos cirúrgicos que envolvessem a aorta. A atividade da doença foi determinada por parâmetros clínicos e laboratoriais. As medições de VOP-CF foram obtidas pelo Sistema Complior. Resultados: A média de VOP-CF foi maior em pacientes com arterite de Takayasu do que em controles (9,77 ± 3,49 vs. 7,83 ± 1.06 m/s, p = 0,009). Apesar dos rigorosos xv critérios de seleção, os pacientes com arterite de Takayasu ainda apresentavam, em média, pressão arterial sistólica de 8 mmHg maior do que os controles (p > 0,05), e os valores de pressão de pulso significativamente mais elevados. O modelo de regressão linear múltipla mostra que 93,8% da variabilidade da VOP é explicada pelas variáveis idade, pressão arterial média (PAM) e pela própria doença (R2 ajustado = 0,938). A análise logística stepwise usando como variável dependente o valor de corte de VOP estabelecido pela curva ROC (> 8,34 m/s) e, como variáveis independentes, os parâmetros com significância na análise univariada, revelou que arterite de Takayasu (OR: 4,69, IC 95% 1,31 - 16,72; p = 0,017) e PAM (OR: 1,06, IC 95% 1,00 - 1,12, p = 0,048) foram independentemente associados a maior VOP. Uma análise mais aprofundada dos parâmetros de doença revelou que os valores de VOP não foram correlacionados com velocidade de hemossedimentação, proteína C-reativa, dose cumulativa de glicocorticoides e fração de ejeção (p > 0,05). Conclusão: Nesta coorte de pacientes do sexo feminino com arterite de Takayasu, a própria doença e a pressão arterial média foram os determinantes mais fortemente associados com elevada rigidez arterial e não houve correlação dos valores de VOP com parâmetros de atividade da doença / Takayasu arteritis (TA) is a granulomatous vasculitis that affects the aorta and large vessels and is associated with higher cardiovascular risk. Pulse wave velocity (PWV) is a method of indirect evaluation of decreased arterial distensibility, and elevated PWV correlates with increased cardiovascular morbidity and mortality. The assessment of PWV in patients with Takayasu arteritis is complex due to many confounding factors. The aim of this study was to evaluate arterial stiffness, assessed by carotid-femoral pulse wave velocity (CF-PWV) in female patients with TA and healthy controls with comparable anthropometric and clinical variables, and the possible association with parameters of the disease. Method: Patients with TA (n = 27) were consecutively evaluated and healthy controls were selected with comparable age, blood pressure, weight and height (n = 27). Exclusion criteria were menopause, smoking, diabetes, renal insufficiency, poorly controlled hypertension, cardiac arrhythmias, obesity, inflammatory comorbidities, pregnancy and history of surgical procedures involving the aorta. Disease activity was determined by clinical and laboratory parameters. The CF-PWV measurements were obtained by the Complior System. Results: The mean CF-PWV was higher in patients with TA than in controls (9.77 ± 3.49 vs. 7.83 ± 6.1 m / s, p = 0.009). Despite the strict selection criteria, TA patients still had, on average, systolic blood pressure of 8 mmHg greater than controls (p > 0.05), and pulse pressure values significantly higher. The multiple linear regression model showed that 93.8% of the variability in PWV is explained by the variables age, mean arterial pressure (MAP) and the disease itself (adjusted R2 = 0.938). A stepwise logistic analysis using as the dependent variable the cutoff value of VOP established by the ROC curve (> 8.34 m/s) and, as independent variables, parameters with significance in the univariate analysis, revealed that Takayasu arteritis (OR: 4.69 95% CI 1.31 - 16.72, p = 0.017) and MAP (OR: 1.06, 95% CI 1.00 - 1.12, p = 0.048) were independently associated with increased PWV. Further analysis of disease parameters revealed that PWV values were not correlated with erythrocyte sedimentation rate, C-reactive protein, cumulative dose of glucocorticoids or ejection fraction (p > 0.05). Conclusion: In this cohort of female patients with Takayasu arteritis, the disease itself and mean arterial pressure were determinants most strongly associated with elevated arterial stiffness and no correlation of PWV values and parameters of disease activity was found

The objectives of this thesis were: (1) to evaluate the downregulation of the stallion hypothalamic-pituitary-gonadal (HPG) axis by a GnRH antagonist (acyline) based upon endocrine, seminal, testicular and behavioral effects, and (2) to assess recovery after treatment. Stallions were treated for 50 days (n=4; 330µg/kg acyline q 5d) and controls (n=4) received vehicle alone. Stallions were assessed pre-treatment and for 72 days after last treatment. Treatment induced declines (p<0.05) in FSH, LH, testosterone (to castrate levels) and estrone sulfate. Gonadotropins and testosterone returned to control values within nine days and estrone sulfate by 14 days after treatment discontinuation. Acyline-treated stallions failed to respond with FSH, LH and testosterone increase after exogenous GnRH stimulation (25µg gonadorelin, IV) compared to pre-treatment and control stimulation. Total sperm numbers and motility were reduced in acyline-treated stallions, as well as total seminal plasma protein and testicular volume (p<0.05). Time to ejaculation was increased in acyline group (p<0.5). Testicular, sexual behavior and most seminal parameters regained normal levels within 72 days after treatment ceased. Sperm output of acyline-treated stallions was regained within seven months after ending treatment. Acyline reversibly suppressed the stallion HPG axis, thus has potential for treating the androgen-dependent Equine-Arteritis-Virus carrier state and as behavior modulator.

Le virus de l’Artérite Virale Équine (EAV) est un virus à ARN simple brin positif, appartenant à la famille des Arteriviridae, dans l’ordre des Nidovirales. C’est un virus spécifique des équidés qui peut être transmis par voies respiratoire et vénérienne. Lors de la primo-infection, l’EAV peut entraîner des signes cliniques grippaux, mais de façon plus grave, il peut aussi provoquer l’avortement des juments gestantes ainsi que la mort des nouveau-nés. L’EAV représente donc un enjeu économique majeur pour la filière équine. Suite à la primo-infection, ce virus peut persister dans de l’appareil reproducteur de certains étalons. Les mécanismes de cette persistance ne sont pas connus.Au cours de cette thèse, le premier modèle in vitro d’infection non lytique d’une lignée issue de l’appareil reproducteur mâle par l’EAV a été développé. L’infection de ces cellules de Leydig a montré une induction de l’expression de nombreux gènes de l’immunité innée dont ceux codant pour des cytokines pro-inflammatoires et des chimiokines qui permettraient le recrutement de cellules de l’immunité innée au niveau des testicules, et qui pourraient expliquer l’orchite observée chez certains étalons lors de la phase aiguë de l’infection. Pour les étalons infectés de façon persistante, la castration et les traitements anti-GnRH peuvent permettre la suppression de la persistance du virus, suggérant ainsi une implication de la testostérone dans la persistance du virus. Les cellules TM3 exprimant le récepteur aux androgènes, des essais de traitements ont été réalisés. Les premiers résultats préliminaires semblent indiquer que les cellules TM3 ne répondent pas ou peu au stimulus hormonal. Cependant, des tests de prétraitement par la testostérone seraient à envisager afin d’en étudier les conséquences sur le cycle viral. Ce modèle d’infection non lytique reste cependant un modèle intéressant pouvant être utilisé afin d’étudier les relations hôte-pathogène et pouvant aider à comprendre les mécanismes impliqués dans la persistance de l’EAV. / Equine Arteritis Virus (EAV) is a positive-strand RNA virus, which belongs to the Arteriviridae familly, in the Nidovirales order. It is an equid specific virus that can be transmitted by respiratory and venereal routes. During primary infection, EAV can induce flu-like clinical signs, but worse, it may also cause the abortion of pregnant mares and newborn foal death. EAV is therefore a main economic challenge for the horse industry. Following primary infection, this virus is able to persist in the reproductive tract of some stallions. The mechanisms of this persistence remain unknown.During this thesis, the first in vitro model of an EAV non-lytic infection of a male reproductive tract cell line has been developed. EAV infection of these Leydig cells induced the expression of numerous innate immune genes including those coding for pro-inflammatory cytokines and chemokines, which could recruit innate immune cells to testicles and which could explain the orchitis observed in some stallions during primary infection.For persistently infected stallions, castration and anti-GnRH treatments can suppress EAV persistence, suggesting an involvement of testosterone in the virus persistence. Since TM3 cells express the androgen receptor, treatment trials have been performed. The first preliminary results suggest TM3 cells do not respond to the hormonal stimulus, or only a little. However, pretreatment trials should be realized to study the consequences on the viral cycle.Nevertheless, this non-lytic infection model is still an interesting model that can be used to study the host-pathogen relationship and that could help understanding the mechanisms involved in EAV persistence.

Made available in DSpace on 2014-08-20T14:37:53Z (GMT). No. of bitstreams: 1 dissertacao_debora_scopel.pdf: 765310 bytes, checksum: dc0bea20bd4a62c37e4145ef858b7894 (MD5) Previous issue date: 2013-02-27 / The development and use of drugs with the ability to prevent or strike an infection are indispensable for human and animal health. However, the antiviral drug arsenal is still small and has serious use restrictions, like small activity range, limited therapeutic usage and several degrees of cytotoxicity. The objective of this work was to evaluate the antiviral activity of an antibacterial peptide isolated from the intestinal contents of the fish Piau-com-pinta (Leporinus sp.), named P34. Its cytotoxicity was analyzed in different cell lineages, in order to evaluate its antiviral activity. This study was performed against viruses with different phenotypical and genotypical features like: canine adenovirus type 2 (CAV-2), canine coronavirus (CCoV), canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), equine arteritis virus (EAV), equine influenza virus (EIV), feline calicivirus (FCV) and feline herpesvirus type 1 (FHV-1). It was observed antiviral activity, in vitro, against EAV and FHV-1, both enveloped viruses, with RNA e DNA genomes, respectively. A virucidal effect was observed when P34 was incubated for different periods of time with EAV at 37 °C. Transmission electronic microscopy analysis suggests that the peptide P34 binds and promotes lesions to the viral envelope. The peptide P34 does not have virucidal activity against FHV-1 and although its mechanism of action is not completely elucidated, it is possible to suppose that P34 interferes in the adsorption process of FHV-1. Thus, the peptide P34 may represent an antimicrobial substance with potential application in the prevention and treatment of viral infections caused by FHV-1 and EAV. / O desenvolvimento e o uso de fármacos antivirais capazes de prevenir ou combater uma infecção são imprescindíveis para a saúde do homem e dos animais. Entretanto, o arsenal de fármacos antivirais permanece pequeno e apresenta graves restrições de uso, tais como reduzido espectro de atividade, utilidade terapêutica limitada e vários graus de toxicidade. O objetivo desse trabalho foi avaliar atividade antiviral de um peptídeo antibacteriano isolado do conteúdo intestinal do peixe Piau-com-pinta (Leporinus sp.), denominado P34. Sua citotoxicidade foi determinada em diferentes linhagens celulares, visando posterior avaliação da atividade antiviral. Foram realizados ensaios antivirais frente a vírus com diferentes características genotípicas e fenotípicas: adenovírus canino tipo 2 (CAV-2), coronavírus canino (CCoV), vírus da cinomose canina (CDV), parvovírus canino tipo 2 (CPV-2), vírus da arterite equina (EAV), vírus da influenza equina (EIV), calicivírus felino (FCV) e herpesvírus felino tipo 1 (FHV-1). Foi observada ação antiviral, in vitro, contra EAV e FHV-1, ambos vírus envelopados, com genomas RNA e DNA, respectivamente. Foi observado efeito virucida, contra o EAV, quando o P34 foi incubado por diferentes períodos a 37 °C. A análise por microscopia eletrônica de transmissão sugere que o peptídeo P34 faz ligação e promove lesão do envelope viral. O P34 não possui atividade virucida contra o FHV-1 e embora o mecanismo de ação não tenha sido completamente elucidado, é possível supor que o P34 interfira no processo de adsorção do FHV-1. Dessa maneira, o peptídeo P34 pode representar uma substância com potencial aplicação na prevenção e tratamento das infecções pelo FHV-1 e pelo EAV.

Rationnel : L’artérite à cellules géantes (ACG) est une vascularite primitive des gros vaisseaux dont le diagnostic repose sur la mise en évidence d’un infiltrat inflammatoire et de cellules géantes à la biopsie d’artère temporale (BAT). On note également un remodelage de la paroi vasculaire lié à une prolifération des cellules musculaires lisses vasculaires (CMLV) pouvant aboutir à une occlusion artérielle. Objectif : Caractériser les auto-anticorps dirigés contre les cellules endothéliales (CE) et les CMLV au cours de l’ACG et préciser le rôle des CMLV dans le remodelage pariétal. Méthodes : La recherche d’auto-anticorps a reposé sur un immunoblot 2D couplé à la spectrométrie de masse. Les protéomes des CMLV d’artère ombilicale, d’artère pulmonaire et d’aorte humaines normales a été comparés par protéomique différentielle (2D-DIGE). Nous avons utilisé la 2D-DIGE et des puces d’expression pan-génomiques pour comparer les CMLV issues de BAT de patients suspects d’ACG (avec un diagnostic final d’ACG ou non), afin d’identifier les mécanismes contribuant à la prolifération des CMLV. Résultats : Chez 15 patients atteints d’ACG, nous avons notamment identifié la lamine, la vinculine et l’annexine A5 comme cible des auto-anticorps anti-CMLV. Les antigènes cibles identifiés sont liés à Grb2, une protéine adaptatrice impliquée dans la prolifération des CMLV. Nous avons mis en évidence des protéomes différents au sein des CMLV humaines normales selon leur origine vasculaire et avons principalement identifié des protéines du cytosquelette et du métabolisme énergétique.A partir des CMLV isolées des BAT et à l’aide d’Ingenuity®, nous avons identifié l’endothéline 1 (ET-1) et la paxilline comme des molécules impliquées dans le remodelage vasculaire. En immunohistochimie et par qPCR, nous avons confirmé l’expression de l’ET-1 et de ses récepteurs ETAR et ETBR au sein des artères temporales de patients atteints d’ACG. Enfin, nous avons inhibé la prolifération des CMLV avec du macitentan, un inhibiteur d’ETAR et en particulier avec son métabolite actif, mais pas avec d’autres inhibiteurs des récepteurs de l’ET-1. Conclusion : Nous avons identifié chez les patients atteints d’ACG des anticorps anti-CMLV dont le rôle pathogéne potentiel reste à définir. Les différences protéiques observées à partir des CMLV humaines normales pourraient correspondre à des phénotypes différents. A partir d’un matériel biologique unique, nous avons pu montrer que la prolifération excessive des CMLV au cours de l’ACG pouvait être inhibée par le macitentan ce qui permet d’envisager un usage thérapeutique de cette molécule. / Background : Giant cell arteritis (GCA) is a large vessel vasculitis and its diagnosis usually relies on the identification of an inflammatory infiltrate made of mononuclear cells and giant cells upon temporal artery biopsy. There is also a remodeling process in the arterial wall due to an excessive proliferation of vascular smooth muscle cells (VSMC) which can sometimes lead to arterial occlusion. Purpose: Identify auto-antibodies targeting either endothelial cells (EC) and/or VSMC during GCA and better understand the role of VSMC in the remodeling process. Methods : Auto-antibodies were detected by a 2-dimensionnal immunoblot and their target antigens were identified by mass spectrometry. Proteoms of umbilical artery, pulmonary artery and aorta VSMC were compared by 2 dimension differential in gel electrophoresis (2D-DIGE). In order to identify mechanisms involved in VSMC proliferation in GCA, we used both 2D-DIGE and pan genomic chips in order to compare VSMC isolated at the time of temporal artery biopsy (TAB) from patients with a final diagnosis of GCA or another diagnosis. Results : In 15 patients with GCA, we identified lamin, vinculin and Annexin A5 as target antigens of anti-VSMC antibodies. Target antigens were linked with Grb2, an adaptator protein involved in VSMC proliferation. Normal VSMC originating from different vascular beds have differ in protein contents with differential expression of cytoskeleton and energy metabolism proteins. We compared VSMC from TAB with Ingenuity software and identified endothelin-1 (ET-1) and paxillin as proteins involved in vessel remodeling. We confirmed by immunohistichemistry and qPCR that ET-1 and its receptor ETAR and ETBR were expressed in temporal arteries from patients with GCA. Last, we reduced VSMC proliferation with Macitentan, an ETAR and ETBR antagonist and significantly inhibited VSMC proliferation with its active metabolite whereas other ET-1 inhibitors had no effect. Conclusion : We identified anti-VSMC auto-antibodies in patients with GCA. Their pathogenic role remains to be determined. Normal VSMC from different vascular locations differ in protein conten which might reflect different phenotypes and different properties. The escessive proliferation of VSMC from patients with GCA was inhibited by Macitentan. This drug might constitute a future therapeutic option.

No description available.

Im Zuge der Überarbeitung der DVG-Richtlinie zur Prüfung der Viruzidie chemischer Desinfektionsmittel in der Nutztierhaltung wurden BVDV, EAV und PPV auf ihre Eignung als potentielle Prüfviren getestet. Das bisher vorgeschriebene Newcastle-Disease-Virus und das Vacciniavirus sollen mit anderen behüllten Viren wie BVDV oder EAV verglichen werden. Beweggründe für einen möglichen Austausch sind die derzeitige Situation in der Tierseuchenbekämpfung, die Erhöhung der Anwendersicherheit durch Wegfall des zoonotischen Potentials, die einfachere Kultivierung und Handhabung der Prüfviren sowie speziell bei NDV die höhere Aussagekraft der gewonnenen Ergebnisse. Die Desinfektionsmittelversuche wurden gemäß DVG-Richtlinie auf Pappelholzkeimträgern durchgeführt, wobei das jeweilige, mit fetalem Kälberserum vermischte, Virus auf die Keimträger aufgetragen und angetrocknet wurde. Die DVG schreibt eine Trocknung im Brutschrank von 60 Minuten bei 37°C vor. Um die Trocknungsverluste der eingesetzten Viren zu untersuchen, wurden vergleichende Trocknungsversuche wie vorgeschrieben im Brutschrank und im Exsikkator bei Raumtemperatur durchgeführt. Die nach der Trocknung im Brutschrank durchgeführten Desinfektionsmittelversuche wurden mit chemischen Grundsubstanzen kommerziell erhältlicher Desinfektionsmittel durchgeführt. Dabei kamen verschiedene Anwendungskonzentrationen von Ameisensäure, Glutaraldehyd, Natriumhypochlorit, Natronlauge und Peressigsäure zum Einsatz. Bei der vorgeschriebenen Trocknung im Brutschrank kam es zu Titerverlusten von 0,8 bis zu 2,75 log10KID50/ml. Durch eine Trocknung der Holzkeimträger von 30 Minuten bei Raumtemperatur im Exsikkator konnten die Titerverluste auf 0,3 bis 1,0 log10KID50/ml reduziert werden. In den nachfolgenden Desinfektionsversuchen zeigte sich die besonders hohe Tenazität von PPV. Es war den eingesetzten Desinfektionsmitteln gegenüber deutlich resistenter als alle anderen untersuchten Viren. In den Trocknungsversuchen zeigte PPV mit Abstand die niedrigsten Titerverluste. Mit BVDV und EAV konnten zwar ausreichend hohe Titer erzielt werden, allerdings waren die Trocknungsverluste beider Viren sehr hoch. In den Keimträgerversuchen konnte nur in wenigen Versuchen eine Titerreduktion von mehr als 3 Logarithmusstufen erreicht werden. Hier könnte zukünftig die Trocknung im Exsikkator Abhilfe schaffen, um die Trocknungsverluste zu minimieren und eine höhere Titerreduktion zu ermöglichen. Die Ergebnisse einer früheren Arbeit zeigen identische Ergebnisse von NDV und BVDV im Keimträgertest. Ein Ersatz von NDV durch BVDV ist somit zu empfehlen. Eine Verwendung der untersuchten Viren gemäß den derzeitigen DVG-Richtlinien ist möglich, allerdings müssten im Zuge der weiteren Harmonisierung von CEN- und DVG-Richtlinie die Kontrolltiter entsprechend erhöht werden, um die von der CEN geforderte Titerreduktion von vier Logarithmusstufen für eine vollständige Virusinaktivierung einzuhalten. Die Vermehrung der untersuchten Viren zu höheren Ausgangs-, bzw. Kontrolltitern sollte daher Gegenstand weiterer Forschungsarbeit sein. Einer weiteren Verwendung der bisherigen Prüfviren BEV und REOV steht nichts im Wege. Aufgrund der Ergebnisse der vergleichenden Trocknungsversuche wird für alle untersuchten Viren zukünftig eine 30 minütige Trocknung im Exsikkator empfohlen.

Desinfektionsmittel sind ein elementarer Bestandteil der Tierseuchenbekämpfung und damit auch der Lebensmittelsicherheit. Die Prüfung chemischer Desinfektionsmittel ist Voraussetzung für deren zuverlässige Wirksamkeit und zielgerichteten Einsatz. In Deutschland geschieht dies nach den Richtlinien der Deutschen Veterinärmedizinischen Gesellschaft e.V. (DVG). Seit der ersten Fassung sind die Richtlinien einem ständigen Anpassungsprozess unterworfen. Im Zuge der europäischen Harmonisierung gilt es nun, sich gesamteuropäischen Richtlinien, verfasst durch das europäische Komitee für Normung (Comité Européen de Normalisation) (CEN) anzupassen. Das Thema dieser Arbeit entwickelte sich im Kontext der derzeitigen Diskussion über Verbesserungsvorschläge zu den bestehenden Richtlinien und deren Anpassung an die europäischen Normen. Es wurden je zwei Testviren für die Bereiche Tierhaltung und tierärztliche Praxis ausgewählt, um sie auf Eignung für die Viruzidieprüfung zu testen und gegebenenfalls zu etablieren. Des Weiteren wurde in einem zweiten Teil, in Anlehnung an die Forderungen der europäischen Normen die Prüfung zu vereinfachen, ein alternatives Zellkulturnachweissystem für das Newcastle-Disease-Virus (NDV) geprüft. Die Prüfung der viruziden Wirksamkeit erfolgte mit fünf verschiedenen Grundsubstanzen, gewählt um ein möglichst breites Spektrum an Desinfektionsmittelwirkstoffen abzudecken. Es wurden Glutaraldehyd, Ethanol, Natronlauge, Natriumhypochlorit und Peressigsäure verwendet. Die Versuche wurden mit einer niedrigen Eiweißbelastung und bei einer Temperatur von 20°C durchgeführt. Um eine praxisnahe Situation zu simulieren wurde auf, bereits in den DVG-Richtlinien, verankerten Stahl- und Holzkeimträgertests zurückgegriffen. Als mögliche Prüfviren für die Tierhaltung wurden das Equine Arteritis-Virus (EAV) und das Bovine Virus Diarrhoe Virus verwendet. Bei beiden Viren handelt es sich um weit verbreitete Tierseuchenerreger mit einer großen epidemiologischen Bedeutung. Die Untersuchung von fünf verschiedenen Desinfektionsmitteln erfolgte im Keimträgertest auf Holz. Sowohl EAV als auch BVD stellen ein weniger geeignetes Prüfvirus dar, da beide Viren enorme Titerverluste im Trocknungsvorgang der Holzkeimträger zeigten. Die Viren ließen sich zwar leicht vermehren, aber die erzielten Ausgangstiter reichten nicht aus um die Trocknungsverluste zu kompensieren und aussagekräftige Ergebnisse zu produzieren. Für den Bereich tierärztliche Praxis wurden das Feline Coronavirus (FCoV) und das Murine Parvovirus (MPV) genutzt. FCoV ist ein weltweit in Hauskatzenpopulationen vorkommendes Virus mit einer hohen Seroprävalenz und wurde daher ausgewählt. MPV wurde als Stellvertreter für die, in der Praxis häufig vorkommenden Parvovirusinfektionen gewählt. Es schien ein ideales Modellvirus aufgrund seiner weiten Verbreitung in der Forschung zu sein. Bei beiden Viren erfolgte die Prüfung auf Stahlkeimträgern. Unter Laborbedingungen konnte FCoV ohne Probleme zu hohen Titern vermehrt werden. Es gab keine nennenswerten Trocknungsverluste. FCoV erwies sich als geeignetes Prüfvirus. MPV hingegen ist bedingt durch die langen Versuchszeiten und schwierig auszuwertenden Zellkulturen, sowie wegen der niedrigen Ausgangstiter weniger geeignet als Modellvirus für die Desinfektionsmittelprüfung. Die Anzucht von NDV in Allantoisflüssigkeit von SPF Hühnereiern erschien sehr aufwendig und mit hohem Eiweißfehler belastet. In den Versuchen konnte ein deutlich höherer Eiweißgehalt als in den vergleichend geprüften, in Zellkultur angezogenen Viren nachgewiesen werden. Infolge der Probleme mit der Kultivierung der LMH-Zelllinie und den damit verbundenen langen Wartezeiten bis zur eigentlichen Versuchsdurchführung kann nur eine teilweise Empfehlung, von auf Zellkultur vermehrtem NDV (NDV (ZK)) gegeben werden. Nach Behebung dieser Probleme ist durchaus eine Ablösung, von in Allantoisflüssigkeit angezüchtetem NDV durch NDV (ZK) zu empfehlen. Die Verfälschung der Ergebnisse durch die höheren Eiweißgehalte bei Desinfektionsmitteln mit deutlichem Eiweißfehler könnten so vermieden werden.